BEQVEZ™ Gene Tx Approved & 9 more major updates...👇
Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence
🎯 → Approvals
🔬 → New data
🤝 → M&A activity
Pfizer
🎯 FDA approved BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B.
Amneal Pharmaceuticals
🎯 Received FDA approval for OTC Naloxone Hydrochloride nasal spray for emergency treatment of an opioid overdose.
ImmunityBio
🎯 FDA approved ANKTIVA® for BCG-unresponsive non-muscle invasive bladder cancer.
Gilead
🎯 FDA approved Biktarvy® label update with data for pregnant adults with HIV.
BeiGene
🎯 Received European Comm. approval for Tislelizumab as treatment for NSCLC.
AstraZeneca
🎯 Voydeya approved in the EU as an add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia.
Legend Biotech
🎯 EU Comm. approved CARVYKTI® (ciltacabtagene autoleucel) as second-line treatment for r/r MM.
Sensei Biotherapeutics
🔬 Preliminary topline results from the Ph1 DE study of SNS-101, both as a standalone treatment and in combination with cemiplimab, will be presented at ASCO 6/1/24.
Immutep
🔬 Reported preliminary topline result from cohort B of the TACTI-003 Ph2b trial of eftilagimod alpha (efti) + KEYTRUDA® showing a preliminary response rate of 26.9% achieving the primary endpoint of the study. Further data will be released in H1 2024.
Incyte & Escient Pharmaceuticals
🤝 Acquired Escient Pharmaceuticals for $750M acquiring its pipeline of first-in-class oral MRGPR antagonists.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
April 22-26, 2024
Article History:
RF, DV (04/26/24)